Nicox has initiated a phase 2 clinical trial of NCX 4251, an ophthalmic suspension of fluticasone propionate nanocrystals, for the treatment of acute exacerbations of blepharitis.
The multicenter, randomized, double-masked, placebo-controlled, dose-escalation, 14-day trial will evaluate the safety and tolerability of NCX 4251 compared with placebo and is expected to include approximately 30 patients, according to a press release.
The trial’s main objective is to determine the doses of NCX 4251 to advance to phase 2b trials.
“There is no product approved in the United States solely
Uncategorized